Pazopanib
- TRADE NAME: Votrient (Novartis)
- INDICATIONS: Advanced renal cell carcinoma
- CLASS: Angiogenesis inhibitor / antiangiogenic agent, Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Tyrosine kinase inhibitor, Vascular endothelial growth factor (VEGF) inhibitor / antagonist
- HALF-LIFE: 31 hours
Alfuzosin, Artemether/Lumefantrine, Atazanavir, BCG Vaccine, Boceprevir, Cardiac glycosides, Chloroquine, Ciprofloxacin, Clarithromycin, Clozapine, Conivaptan, CYP3A4 inducers or inhibitors, Cyproterone, Darunavir, Deferasirox, Delavirdine, Denosumab, Dronedarone, Efavirenz, Gadobutrol, Grapefruit Juice, Indacaterol, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Leflunomide, Natalizumab, Nelfinavir, Nilotinib, Oxcarbazepine, P-glycoprotein inhibitors, Pimecrolimus, Pimozide, QT prolonging agents, Quetiapine, Quinine, Rifampin, Rifapentine, Ritonavir, Roflumilast, Saquinavir, Simvastatin, Sipuleucel-T, St John's Wort, Tacrolimus, Telithromycin, Tetrabenazine, Thioridazine, Tocilizumab, Toremifene, Trastuzumab, Vaccines, Vandetanib, Vemurafenib, Vitamin K antagonists, Voriconazole, Ziprasidone
PREGNANCY CATEGORY: D
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
Page last updated 08/03/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
